



**DIABLO CHAPTER
CALIFORNIA SOCIETY OF HEALTH
SYSTEM PHARMACISTS**

Mission: To Promote Wellness, Patient Safety and Optimal Use of Medications



Laura Polonsky, President, Delegate
Keith Yoshizuka, Immed Past-President
Edlen Wong, President Elect, Delegate

Derek Dwinell, Treasurer

Rod Zimmerman, Secretary

Diana Thamrin **Johnny Wong**
Frank Choy
Directors

Catherine Song
New Practitioner Director

Barbara Uenaka **Phipson Wu**
Nam Fuji Do
Education Chairs

Judy Lee **Alvin Tong**
Barbara Uenaka **Alfonso Becerra**
Natalie Fan **Martin Iyoya**
Linda Kan-Huey
Delegates

Lester Wong **Jeff Chen**
Alternate Delegates

Edlen Wong, Chair
Members - TBD
Nominations Committee

Natalie Fan **Yolanda Ramos**
CAPE Accreditation Chairs

Tiffany Rendon **Rajkumar Saharan**
Monica Ukaoma **Jeff Chen**
NOWI Chairs

Donna Fitzgerald **Rachael Ortiz**
Technician Liaisons

Monica Ukaoma **Maneesha Deo**
Fanny Tan **Mauricio Ortega**
Nour Itani
Resident Program CE Chairs

Elizabeth Vuong
Newsletter

TBD
Community Outreach

Donna Fitzgerald
Webmasters

Rachael Ortiz
DSHP Membership Chair

Keith Yoshizuka
Government Affairs Chair

Donna Fitzgerald
CSHP Board Liaison

Umang Patel **Roma Bhandarkar**
Zeenal Patel
Diabetes Community Outreach Chairs

Umang Patel **Roma Bhandarkar**
Zeenal Patel
Social Events Chair

Corinna Lee
Natalie Sweeney
Industry Liaisons

The Diablo Society of Health-System Pharmacists

**Cordially invites you to attend an
Accredited CE Dinner Program
*Presented by***

Danning Ma, Pharm.D.

PGY-2 Pharmacy Resident

Kaiser Permanente Diablo Service Area

**“Evolving Role of Poly ADP-Ribose Polymerase (PARP)
Inhibitors in Cancer Management”**

Goal Statement: To explain the proper utilization of PARP inhibitors and explore new frontiers of PARP inhibition in cancer therapy, including current and emerging trial data in breast, ovarian and prostate cancers.

Learning Objectives:

- Examine the mechanism of action of PARP inhibitors and assess how their pharmacology exploits the concept of “synthetic lethality” in *BRCA*-mutated cancer cells.
- Investigate evidence of safety and efficacy profiles of currently-approved PARP inhibitors for ovarian, breast and prostate cancers.
- Explore current ongoing clinical development of PARP inhibitors for the treatment of ovarian, breast, and prostate cancers.
- Review the administration, side effect profiles, drug-drug interactions and counseling points pertaining to PARP inhibitors.

Tuesday, May 14th, 2019

6:30 Registration and Dinner

7:00 Presentation

Kaiser Permanente Walnut Creek

**Oak 2 on the 3rd Floor Medical Office Building
1425 South Main Street, Walnut Creek, CA 94596**

RSVP BY FILLING OUT ATTACHED FORM

Include address & phone, title & facility,

License # by noon on 05/11/19

Seats are limited. RSVP ASAP.

1 hour of CE will be provided (Exp 05/14/22)

California Accreditation for Pharmacy Education (CAPE) Provider #123